micro , a few bad things are happening per SEC filings :
Item 5.02, Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. On May 31, 2023, the Company provided notices to Richard Fair, President and Chief Executive Officer, and Charity Scripture, Chief Development Officer that their employment by the Company will terminate on June 30, 2023. In connection with the termination of Mr. Fair’s employment, he will receive severance benefits in accordance with his employment agreement. In connection with the termination of Dr. Scripture’s employment, she will receive severance benefits in accordance with her employment agreement and she will receive COBRA reimbursement for up to 12 months. Payment of severance benefits for each individual is conditioned upon them providing a general release of claims for the benefit of the Company following his or her last day of employment. Each of these officers will enter into consulting agreements with the Company to continue to provide services in their officer capacities as consultants to the Company and will be paid hourly for their services. The Company intends to file the consulting agreements as exhibits to the Company’s Quarterly Report on Form 10Q for the second quarter of 2023.
More importantly filed May 30th :
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed by Bellicum Pharmaceuticals, Inc. (the “Company”), pursuant to a Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 11, 2023, on April 6, 2023, the Company received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s stockholders’ equity as reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 does not satisfy the Nasdaq Capital Market continued listing requirement set forth in Nasdaq Listing Rule 5550(b)(1) (“Rule 5550(b)(1)”).
The Company was given until May 19, 2023 to submit to Nasdaq a plan to regain compliance with Rule 5550(b)(1). The Company did not submit such a plan to Nasdaq.
As a result, on May 24, 2023, the Company received written notification from Nasdaq stating that, subject to the Company’s right to request an appeal, trading of the Company’s common stock will be suspended at the opening of business on June 2, 2023, and a Form 25-NSE will be filed thereafter with the SEC, which will remove the Company’s securities from listing and registration on Nasdaq. The Company does not intend to request an appeal of the delisting determination. The Company anticipates that effective June 2, 2023, the Company’s common stock will commence trading on the OTCQX marketplace under the symbol “BLCM.” Quotes and related Company information will be available at www.otcmarkets.com
Seems it traded on the exchange today but I imagine it will move over to the OTC market on Monday